FDA/HESI Research Roadmap Planning on Hazard and Risk Assessment of Nitrosamine Impurities in Drugs

[Naiffer_Host]

@lucas10mauriz wrote a fantastic summary of his thought and reactions to the meeting

FDA/HESI Collaborative Roadmap: Advancing Hazard and Risk Assessment of Nitrosamine Impurities in Pharmaceuticals

Disclaimer: The summary provided below mirrors my individual perspective as an attendee of the workshop and does not reflect the official position of the FDA/HESI. FDA/HESI Research Roadmap Planning on Hazard and Risk Assessment of Nitrosamine Impurities in Drugs: Over the past five years, a global discussion surrounding the safety of human-use medications has centered on the presence of N-nitrosamines. However, the landscape has evolved since 2021, as the focus has shifted from small nitrosam…

Thanks Lucas!